Humacyte (HUMAW) Short Interest Ratio & Short Volume $1.95 +0.10 (+5.41%) (As of 05:22 PM ET) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends Humacyte Short Interest DataHumacyte (HUMAW) has a short interest of 700 shares. This marks a 133.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 30,126 shares to cover all short positions.Current Short Interest700 sharesPrevious Short Interest300 sharesChange Vs. Previous Month+133.33%Dollar Volume Sold Short$973.00Short Interest Ratio0.0 Days to CoverLast Record DateJune 30, 2024Today's Trading Volume19,379 sharesAverage Trading Volume30,126 sharesToday's Volume Vs. Average64% Short Selling Humacyte? Sign up to receive the latest short interest report for Humacyte and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartHUMAW Short Interest Over TimeHUMAW Days to Cover Over TimeHUMAW Percentage of Float Shorted Over Time Ad DTI[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.Tap here to read it Humacyte Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/2024700 shares $973.00 +133.3%N/A0 $1.39 6/15/2024300 shares $603.00 No ChangeN/A0 $2.01 5/31/2024300 shares $672.00 -85.7%N/A0 $2.24 5/15/20242,100 shares $2,562.00 -19.2%N/A0.1 $1.22 4/30/20242,600 shares $1,689.74 -39.5%N/A0.2 $0.65 4/15/20244,300 shares $2,360.27 -18.9%N/A0.3 $0.55 Get the Latest News and Ratings for HUMAW and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. 3/31/20245,300 shares $3,180.00 -29.3%N/A0.3 $0.60 3/15/20247,500 shares $4,994.25 -46.8%N/A0.5 $0.67 2/29/202414,100 shares $12,193.68 +729.4%N/A1 $0.86 2/15/20241,700 shares $1,143.25 +1,600.0%N/A0.1 $0.67 1/31/2024100 shares $45.75 -97.1%N/A0 $0.46 1/15/20243,400 shares $1,363.74 +1,033.3%N/A0.4 $0.40 12/31/2023300 shares $124.77 -75.0%N/A0 $0.42 12/15/20231,200 shares $567.12 +9.1%N/A0.2 $0.47 11/30/20231,100 shares $528.00 -47.6%N/A0.2 $0.48 11/15/20232,100 shares $1,134.00 -65.6%N/A0.3 $0.54 10/31/20236,100 shares $2,623.00 -43.0%N/A1 $0.43 10/15/202310,700 shares $7,276.00 -32.3%N/A2.2 $0.68 9/30/202315,800 shares $11,336.50 +192.6%N/A3.8 $0.72 9/15/20235,400 shares $4,330.80 -10.0%N/A1.3 $0.80 8/31/20236,000 shares $5,226.00 -35.5%N/A1.4 $0.87 8/15/20239,300 shares $8,872.20 -1.1%N/A1.8 $0.95 7/31/20239,400 shares $7,510.60 -16.1%N/A1.4 $0.80 7/15/202311,200 shares $8,954.40 +7.7%N/A0.9 $0.80 6/30/202310,400 shares $7,592.00 +73.3%N/A0.7 $0.73 6/15/20236,000 shares $5,400.00 -15.5%N/A0.4 $0.90 5/31/20237,100 shares $6,674.00 -39.3%N/A0.5 $0.94 5/15/202311,700 shares $10,413.00 +7.3%N/A0.9 $0.89 4/30/202310,900 shares $6,322.00 -34.3%N/A0.9 $0.58 4/15/202316,600 shares $10,225.60 +7.1%N/A2.4 $0.62 3/31/202315,500 shares $9,300.00 +42.2%N/A2.5 $0.60 3/15/202310,900 shares $7,384.75 +122.5%N/A1.1 $0.68 2/28/20234,900 shares $2,695.00 +6.5%N/A0.4 $0.55 2/15/20234,600 shares $2,847.86 -42.5%N/A0.4 $0.62 1/31/20238,000 shares $4,480.00 -27.9%N/A0.7 $0.56 1/15/202311,100 shares $6,547.89 -51.7%N/A1.1 $0.59 12/30/202223,000 shares $9,029.80 -35.2%N/A2.2 $0.39 HUMAW Short Interest - Frequently Asked Questions What is Humacyte's current short interest? Short interest is the volume of Humacyte shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 700 shares of HUMAW short. Learn More on Humacyte's current short interest. Is Humacyte's short interest increasing or decreasing? Humacyte saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 700 shares, an increase of 133.3% from the previous total of 300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Humacyte's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Humacyte: Alvotech (0.08%), Pharvaris (1.19%), SNDL Inc. (1.81%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($3.71 billion), TC Energy Co. ($2.95 billion), Moderna, Inc. ($2.63 billion), Royal Caribbean Cruises Ltd. ($2.53 billion), Paychex, Inc. ($2.03 billion), Cencora, Inc. ($2.03 billion), Tractor Supply ($1.91 billion), Rivian Automotive, Inc. ($1.78 billion), Chesapeake Energy Co. ($1.50 billion), and United Therapeutics Co. ($1.40 billion). View all of the most shorted stocks. What does it mean to sell short Humacyte stock? Short selling HUMAW is an investing strategy that aims to generate trading profit from Humacyte as its price is falling. HUMAW shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Humacyte? A short squeeze for Humacyte occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HUMAW, which in turn drives the price of the stock up even further. How often is Humacyte's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HUMAW, twice per month. The most recent reporting period available is June, 30 2024. More Short Interest Resources from MarketBeat Related Companies 180 Life Sciences Short Squeeze Alvotech Short Squeeze Alvotech Short Squeeze Atlantic Coastal Acquisition Corp. II Short Squeeze Biofrontera Short Squeeze BriaCell Therapeutics Short Squeeze Celularity Short Squeeze Clene Short Squeeze Cyclo Therapeutics Short Squeeze enGene Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:HUMAW) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.